Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP)

Market Open
2 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
35. 17
-2.13
-5.71%
$
256.69M Market Cap
- P/E Ratio
0% Div Yield
575,481 Volume
-1.57 Eps
$ 37.3
Previous Close
Day Range
35.02 38.13
Year Range
6.76 130
Want to track TNXP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 39 days

Summary

TNXP trading today lower at $35.17, a decrease of 5.71% from yesterday's close, completing a monthly decrease of -12.07% or $4.83. Over the past 12 months, TNXP stock gained 3.44%.
TNXP is not paying dividends to its shareholders.
The last earnings report, released on May 22, 2025, exceeded the consensus estimates by 0.45%. On average, the company has fell short of earnings expectations by -2.21%, based on the last three reports. The next scheduled earnings report is due on Aug 11, 2025.
Tonix Pharmaceuticals Holding Corp. has completed 9 stock splits, with the recent split occurring on Feb 05, 2025.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

TNXP Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone mTNX-1700 treatment was associated with activation of cancer-killing CD8+ T Cells and limiting neutrophil-mediated immune evasion TNX-1700 (hTFF2-HSA fusion protein) is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the publication of a paper entitled, “A CXCR4 Partial Agonist, Improves Immunotherapy by Targeting Immunosuppressive Neutrophils and Cancer-Driven Granulopoiesis,”1 in the peer-reviewed journal Cancer Cell, that represents a collaboration between scientists at Tonix and Columbia University's Medical School and presents data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival and decreased metastases in animal models of gastric cancer.

Globenewswire | 1 day ago
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the open of U.S. equity markets today, June 30, 2025, as part of the 2025 Russell indexes reconstitution.

Globenewswire | 3 days ago
Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

I'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved market; FDA decision is due August 15th, and approval could dramatically boost Tonix's revenue. Tonix has its work cut out for it, but I'm a firm believer that they could have a first-mover advantage in this market.

Seekingalpha | 2 weeks ago

Tonix Pharmaceuticals Holding Corp. Dividends

TNXP is not paying dividends to its shareholders.

Tonix Pharmaceuticals Holding Corp. Earnings

11 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
22 May 2025 Date
-
Cons. EPS
-
EPS
31 Mar 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
9 Aug 2024 Date
-
Cons. EPS
-
EPS
TNXP is not paying dividends to its shareholders.
11 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
22 May 2025 Date
-
Cons. EPS
-
EPS
31 Mar 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
9 Aug 2024 Date
-
Cons. EPS
-
EPS

Tonix Pharmaceuticals Holding Corp. (TNXP) FAQ

What is the stock price today?

The current price is $35.17.

On which exchange is it traded?

Tonix Pharmaceuticals Holding Corp. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is TNXP.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 256.69M.

When is the next earnings date?

The next earnings report will release on Aug 11, 2025.

Has Tonix Pharmaceuticals Holding Corp. ever had a stock split?

Tonix Pharmaceuticals Holding Corp. had 9 splits and the recent split was on Feb 05, 2025.

Tonix Pharmaceuticals Holding Corp. Profile

Biotechnology Industry
Healthcare Sector
Seth Lederman CEO
NASDAQ (CM) Exchange
890260839 Cusip
US Country
81 Employees
- Last Dividend
5 Feb 2025 Last Split
10 May 2012 IPO Date
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Contact Information

Address: 26 Main Street
Phone: 862 799 8599